[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU4133997A - Pharmaceutical composition for the treatment of syndrome x of reaven - Google Patents

Pharmaceutical composition for the treatment of syndrome x of reaven

Info

Publication number
AU4133997A
AU4133997A AU41339/97A AU4133997A AU4133997A AU 4133997 A AU4133997 A AU 4133997A AU 41339/97 A AU41339/97 A AU 41339/97A AU 4133997 A AU4133997 A AU 4133997A AU 4133997 A AU4133997 A AU 4133997A
Authority
AU
Australia
Prior art keywords
reaven
syndrome
treatment
pharmaceutical composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41339/97A
Inventor
Yarom Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11925096A external-priority patent/IL119250A/en
Priority claimed from IL11940396A external-priority patent/IL119403A/en
Application filed by Individual filed Critical Individual
Publication of AU4133997A publication Critical patent/AU4133997A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU41339/97A 1996-09-12 1997-09-10 Pharmaceutical composition for the treatment of syndrome x of reaven Abandoned AU4133997A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL11925096A IL119250A (en) 1996-09-12 1996-09-12 Pharmaceutical composition for the treatment of syndrome x of reaven
IL119250 1996-09-12
IL119403 1996-10-10
IL11940396A IL119403A (en) 1996-10-10 1996-10-10 Pharmaceutical composition for the treatment of syndrome x of reaven
PCT/IL1997/000301 WO1998010786A2 (en) 1996-09-12 1997-09-10 Pharmaceutical composition for the treatment of syndrome x of reaven

Publications (1)

Publication Number Publication Date
AU4133997A true AU4133997A (en) 1998-04-02

Family

ID=26323304

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41339/97A Abandoned AU4133997A (en) 1996-09-12 1997-09-10 Pharmaceutical composition for the treatment of syndrome x of reaven

Country Status (2)

Country Link
AU (1) AU4133997A (en)
WO (1) WO1998010786A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026289B2 (en) 1997-05-13 2006-04-11 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Method and compositions for treating hyperlipidemia and other conditions
WO1998051331A1 (en) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin and somatostatin agonists for decreasing body weight
CA2289499C (en) * 1997-05-13 2010-02-23 Michael Anthony Cawthorne Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
EP1291022A1 (en) * 1998-07-30 2003-03-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Methods of using lanreotide, a somatostatin analogue
CA2335654A1 (en) * 1998-07-30 2000-02-10 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Methods of using a somatostatin analogue
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
HUP0401535A3 (en) * 2001-03-08 2009-07-28 Univ Tulane Somatostatin antagonists and their use
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
EP2208496A1 (en) 2004-08-25 2010-07-21 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
WO2007081521A2 (en) 2006-01-05 2007-07-19 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
EP2395987A1 (en) * 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
EP2819675A4 (en) 2012-02-27 2015-07-22 Essentialis Inc Salts of potassium atp channel openers and uses thereof
EP3166967B1 (en) 2014-09-14 2023-03-08 Tel Hashomer Medical Research Infrastructure and Services Ltd. Synthetic somatostatin receptor ligands
CN107106500B (en) 2014-11-14 2021-07-30 伊森舍丽斯有限公司 Methods for treating subjects with Prader-Willi syndrome or Smith-Magee syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159263A (en) * 1977-05-11 1979-06-26 American Home Products Corporation (D-Ala5)-somatostatin and analogues thereof
US4100153A (en) * 1977-05-11 1978-07-11 American Home Products Corporation (D-Trp5)-somatostatin and analogues thereof
FR2638968B1 (en) * 1988-11-11 1994-10-07 Sandoz Sa NEW THERAPEUTIC USE OF SOMATOSTATIN AND ITS ANALOGS AND DERIVATIVES

Also Published As

Publication number Publication date
WO1998010786A2 (en) 1998-03-19
WO1998010786A3 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
AU2053597A (en) Pharmaceutical compositions for the treatment of glaucoma
AU4762797A (en) Pharmaceutical compositions
AU5136998A (en) Medicinal composition
AU2967597A (en) Pharmaceutical compositions
AU4133997A (en) Pharmaceutical composition for the treatment of syndrome x of reaven
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
AU3777897A (en) Pharmaceutical compositions
AU5317598A (en) Novel pharmaceutical compositions
AU5155096A (en) Pharmaceutical composition
AU2531295A (en) Pharmaceutical composition
AU3460897A (en) Medicinal compositions
AU4644299A (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosisand treatment of anti-phospholipid syndrome
AU2171297A (en) Pharmaceutical compositions and methods for the manufacture thereof
AU2593597A (en) Compositions for the diagnosis and treatment of chediak-higashi syndrome
AU686084B3 (en) Pharmaceutical compositions for the treatment of depressive disorders
AU4326197A (en) Pharmaceutical compositions
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
AUPN862596A0 (en) Pharmaceutical compositions
AU4457597A (en) Pharmaceutical compositions
AU1427895A (en) Pharmaceutical compositions
AU1544195A (en) Pharmaceutical compositions
IL119250A0 (en) Pharmaceutical composition for the treatment of syndrome X of reaven
IL119403A0 (en) Pharmaceutical composition for the treatment of syndrome X of reaven
AU5265596A (en) Composition and method for the treatment of premenstrual syndrome
AU6814496A (en) Pharmaceutical composition